GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Long-Term Capital Lease Obligation

OPHLY (Ono Pharmaceutical Co) Long-Term Capital Lease Obligation : $57 Mil (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co Long-Term Capital Lease Obligation?

Ono Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was $57 Mil.

Ono Pharmaceutical Co's quarterly Long-Term Capital Lease Obligation increased from Jun. 2024 ($0 Mil) to Sep. 2024 ($61 Mil) but then declined from Sep. 2024 ($61 Mil) to Dec. 2024 ($57 Mil).

Ono Pharmaceutical Co's annual Long-Term Capital Lease Obligation declined from Mar. 2022 ($55 Mil) to Mar. 2023 ($50 Mil) and declined from Mar. 2023 ($50 Mil) to Mar. 2024 ($44 Mil).

Ono Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Ono Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co Long-Term Capital Lease Obligation Chart

Ono Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.33 64.67 54.83 49.96 43.73

Ono Pharmaceutical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.90 43.73 - 61.47 57.09

Ono Pharmaceutical Co  (OTCPK:OPHLY) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Ono Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Ono Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Long-Term Capital Lease Obligation
Comparable Companies
TSE:4536 TSE:4151 TSE:4552 TSE:4882 TSE:4503 LLY OCSE:NOVO B JNJ ABBV XSWX:ROG LSE:AZN MRK XSWX:NOVN AMGN PFE GILD XPAR:SAN BMY TSE:4519 LSE:GSK
Traded in Other Exchanges
OPHLF:USA 4528:Japan ON4:Germany
Address
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564
Website
http://www.ono.co.jp
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a world-wide business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.